You are here

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Pubmed ID: 
16942124
Year: 
2006
Volume: 
24
Issue: 
9
Citation: 
Wlodarczyk JH, Cleland LG, Keogh AM, McNeil KD, Perl K, Weintraub RG, Williams TJ. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. PharmacoEconomics 24 (9) : 903 - 15(2006) PubMed